News
Grant Funding Announced for NET Cancer Research
Request for Applications Issued The Neuroendocrine Tumor Research Foundation (NETRF) has announced its latest Request for Applications (RFA) and invites innovative research applications in neuroendocrine
Lessons of NET Cancer
PRRT Patients Tell Their Stories Following the early 2018 FDA approval of the first Peptide Receptor Radionuclide Therapy (PRRT) using lutetium Lu-177 dotatate, many people are
NETRF Welcomes Chief Development Officer
NETRF announces the appointment of Susan Payson as Chief Development Officer. In this new position, Susan will work to expand NETRF’s base of support to
International Gathering Gives Hope
by Laran Hyder, NETRF Associate Director of Development and Outreach As a NET patient or caregiver, living with neuroendocrine cancer can be an isolating experience.
Unraveling the Causes of Small Intestinal NETs
The first step in curing a disease is understanding it. Unfortunately, there is a lot we still don’t know about small-intestinal NETs (SI-NETs). That’s why
Research Today is the Treatment of Tomorrow
by Ronny Allan, NET Patient Activist Doctors and scientists are always looking for better ways to care for patients with cancer; they are looking for
Exercise and Cancer
NETRF Awards Six Grants
NETRF awarded six new research grants totaling $1.85 million to leading academic institutions around the world. The goal of the funding is to improve current treatments for neuroendocrine tumors (NETs), an uncommon and poorly understood cancer, which occurs in the body’s hormone-producing cells.
Paving the road towards powerful targeted therapies
by Effie Tzameli, PhD, NETRF Director of Research The NETRF 2017 Request for Applications (RFA) was designed to invite innovative and transformative translational and clinical